Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;50(4):204-17.
doi: 10.5045/br.2015.50.4.204. Epub 2015 Dec 21.

Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012

Eun-Hye Park  1 , Hyewon Lee  2 , Young-Joo Won  3 , Hee Young Ju  4 , Chang-Mo Oh  1 , Cecile Ingabire  3 , Hyun-Joo Kong  1 , Byung-Kiu Park  4 , Ju Young Yoon  4 , Hyeon-Seok Eom  5 , Eunyoung Lee  2 , Hyeon Jin Park  4
Affiliations

Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012

Eun-Hye Park et al. Blood Res. 2015 Dec.

Abstract

Background: Large-scale epidemiologic analysis for hematologic malignancies will be helpful to understand the trends in incidence and survival.

Methods: The Korea Central Cancer Registry (KCCR) updated the nationwide analysis on the incidence and survival of myeloid malignancies, from the Korean National Cancer Incidence Database between 1999 and 2012. Myeloid malignancies were classified based on the International Classification of Diseases for Oncology 3(rd) edition (ICD-O-3).

Results: Overall 3,771 cases of myeloid diseases, which was 1.7% of all cancers, were identified in 2012. The highest incidence of myeloid malignancies was observed in age 70s and male predominance was noted (1.3:1). Acute myeloid leukemia (AML) was the most frequent subtype, followed by myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) and MDS/MPN: age-standardized incidence rates (ASR) in 2012 for each disease were 2.02, 1.95, 1.13, and 0.12 per 100,000 persons, respectively. The ASR for all myeloid malignancies was increased from 3.31 in 1999 to 5.70 in 2012 with the annual percentage change (APC) of 5.4 %. Five-year relative survival rate (RS) for myeloid malignancies has gradually improved for decades. RS changed from 26.3% to 34.8% in AML, specifically from 51.6% to 69.6% in acute promyelocytic leukemia (APL) and from 23.8% to 29.9% in non-APL AML, between 1996-2000 and 2008-2012. RS also increased from 81.8% to 87.1% in MPN, with a significant improvement in CML (from 74.5% to 85.5%), and from 27.3% to 31.7% in MDS/MPN between 2001-2005 and 2008-2012. However, there was no survival improvement in MDS during the study period (45.6% in 2001-2005 to 44.4% in 2008-2012).

Conclusion: This report updated the nationwide statistical analysis on myeloid malignancies since 2008, showing increasing incidence and improving trends in survival.

Keywords: Incidence; Korea; Myeloid malignancy; Survival.

PubMed Disclaimer

Conflict of interest statement

Authors' Disclosures of Potential Conflicts of Interest: No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1. Incident cases of myeloid malignancies in men (B) and women (C) in Korea, 2012. a)AML cases include 153 cases of APL in both genders (77 cases in men, and 76 cases in women); b)MPN cases include 458 cases of CML in both genders (288 cases in men, and 170 cases in women); c)Unknown cases include 15 cases of acute leukemia, ambiguous lineage in both genders (7 cases in men, 8 cases in women).
Abbreviations: AML, acute myeloid leukemia; MPN, myeloproliferative neoplasms; MDS, myelodysplastic syndrome; MDS/MPN, myelodysplastic/myeloproliferative neoplasms.
Fig. 2
Fig. 2. Incident cases of myeloid malignancies by age group in Korea, 2012.
Abbreviations: same as in Fig. 1.
Fig. 3
Fig. 3. Age-specific incidence rates of myeloid malignancies in men (A) and in women (B) in Korea, 2012.
Abbreviations: same as in Fig. 1.
Fig. 4
Fig. 4. Trend in relative survival rate of myeloid malignances between 1996 and 2010 in Korea.
Abbreviations: same as in Fig. 1.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
    1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951. - PubMed
    1. Percy CL, Fritz AG, Jack A, et al., editors. International classification of diseases for oncology (ICD-O) 3rd ed. Geneva, Switzerland: World Health Organization; 2013.
    1. Marcos-Gragera R, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica. 2011;96:720–728. - PMC - PubMed
    1. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–3734. - PubMed